# Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

Source: https://onco.cc/trials/nct07230301/  
OnCo record `nct07230301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab in pancreatic cancer, run by Sizhen Wang, not yet recruiting.

## Summary

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions is a phase 2, interventional study registered as NCT07230301 by Sizhen Wang, with a registry enrolment figure of 20 participants, started 2025-11-30 and due to reach its primary completion in 2027-06-30. Interventions recorded: Adebrelimab (PD-L1 inhibitor). Conditions listed: Pancreatic Cancer Metastatic. Primary outcome: Overall Survival (OS). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic cancer". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07230301
- Phase: 2
- Setting: Intracavitary Infusion of Adebrelimab Combined With the Best Standard Treatment for the Treatment of Pancreatic Cancer With Pleural and Peritoneal Effusions: A Single-Center, Prospective, Clinical Trial
- Sponsor: Sizhen Wang
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07230301: https://clinicaltrials.gov/study/NCT07230301

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07230301.json